US FDA Approves $40 Twice Yearly HIV Prevention Shot, Opening New Access Opportunities for 120 Countries.

US FDA Approves $40 Twice Yearly HIV Prevention Shot, Opening New Access Opportunities for 120 Countries.

The United States Food and Drug Administration (FDA) has granted tentative approval to a low cost generic version of lenacapavir, a groundbreaking twice-yearly injection designed to prevent HIV infection, marking a significant development in global efforts to expand access to affordable HIV prevention.

The approval, announced on Monday, November 2, 2026, brings the medication closer to wider distribution across 120 low- and middle income countries, particularly in regions where the cost and availability of preventive healthcare remain major challenges.

The generic injection was developed by India’s Dr. Reddy’s Laboratories in collaboration with global health organisations, including Unitaid, the Clinton Health Access Initiative (CHAI), and the Wits Reproductive Health and HIV Institute (Wits RHI).

Under an agreement established in September 2025, the generic version is expected to cost approximately $40 per person annually, making it comparable in price to existing daily oral HIV prevention medication.

Lenacapavir offers an alternative to traditional pre-exposure prophylaxis (PrEP), which generally requires individuals to take preventive medication every day. The injectable version is administered twice annually, potentially improving adherence among people who find daily medication difficult to maintain.

Clinical studies have demonstrated exceptionally high effectiveness, with the injection recording near total protection against HIV infection among participants in major prevention trials.

The development is particularly significant for Africa, where expanding access to effective HIV prevention remains an important public health priority. The continent continues to carry a substantial proportion of the global HIV burden, making affordable and convenient prevention options essential to reducing new infections.

According to the organisations supporting the initiative, initial supplies of the generic medication are expected to reach some countries before the end of 2026, while broader distribution is anticipated in 2027.

However, the FDA’s decision represents tentative approval rather than unrestricted commercial authorisation in the United States. The designation confirms that the generic product meets the agency’s required standards but allows access through applicable international procurement arrangements while the original branded product remains protected by patent restrictions.

The branded version, marketed by Gilead Sciences as Yeztugo, has a reported US list price of approximately $28,218 annually. Generic sales within the United States remain restricted by existing patent protections.

Gilead previously entered voluntary licensing agreements with six generic manufacturers to support the production and distribution of affordable lenacapavir across 120 eligible countries in Africa, Asia and Latin America.

Despite the promising development, public health experts have cautioned that regulatory approval and affordable pricing alone will not guarantee widespread access. Governments will still need to secure funding, complete national regulatory processes, strengthen healthcare delivery systems and ensure adequate supplies.

Medical professionals have also emphasized the importance of HIV testing before treatment begins and before subsequent injections. Administering lenacapavir to someone with an undiagnosed HIV infection can increase the risk of developing drug resistant HIV.

For African countries, including Nigeria, the development presents an opportunity to strengthen existing HIV prevention programmes and widen access to long acting preventive medication. However, the timing of availability will depend on national regulatory approvals, procurement arrangements and distribution plans.

The approval represents an important step towards making advanced HIV prevention more accessible beyond wealthier economies. Whether it translates into meaningful reductions in new infections will ultimately depend on how effectively governments and international partners convert the scientific breakthrough into affordable, reliable and equitable healthcare access.